图为在宁波"阳明文化研习营"活动中，两岸青年了解阳明文化。 中新社记者 刘子琳摄 "以前对大陆的认识更多是抽象的数字，比如GDP增速、市场规模，但这次在平安银行实习，我亲手处 理了跨境金融业务，亲眼见证了大湾区企业的融资需求。"辅仁大学统计信息学系学生庄昀臻近日在广 东广州实习后表示。 "首来族"常常发现大陆和想象中大不相同。"来到这里后，我发现广州这座大都市一点都不冷漠，充满 着人情味。"来自东吴大学法律系的林冠瑜同学说，她将在广东红棉律师事务所实习，努力提高法律文 件撰写、客户沟通与案例分析等能力。 重来大陆的台生，也往往有意料之外的惊喜。来自树德科技大学金融管理系的刘言梁同学8年前曾来过 广州。他说，广州的发展速度让他惊叹。希望通过在浦发银行的实习机会，深入了解大陆的金融市场和 就业环境。 实习实践为深入了解提供契机。在广州，台湾大学生走进玉山银行、红棉律师事务所等机构，近距离观 察粤港澳大湾区金融与法律行业的运作模式；在浙江宁波，他们来到豪雅进出口集团、美康盛德医学检 验所，感受外贸企业与现代医疗技术的创新活力；在上海，科技社团组织台生观摩智能网联汽车中心， 帮助他们了解大陆在科技研发领域的最新成果。 ...

在技术应用推进方面，2000 年日本开启硼中子俘获技术的临床前研究，2016 年逐步开展临床，2020 年 3 月技术获批，6 月便迅速纳入医保。目前，全球仅日本掌握该技术，在辅导、大阪拥有两台临床设 备，而大阪中心还未开放接收国外患者。 从治疗效果与前景来看，该技术首批适应症为头颈部肿瘤，且正在拓展乳腺癌、胰腺癌等适应症。尹烨 提到，在日本已治疗的 800 多例中，部分肿瘤三年生存率达60-70%，虽技术尚有适用症有限、需迭代 等问题，但已展现出巨大潜力，凸显出日本在癌症治疗技术上的独特优势与领先地位。 以下内容整理自采访实录： 《封面》：尹老师，咱们聊聊硼中子俘获治疗技术，这个技术其实挺有渊源的是吧？ 尹烨：实际上这个技术上世纪30年代法国人先发现了类似原理，美国人在50年代搞过一次。上世纪50年 代他们就搞过，当时没区分得特别好，治疗效果"惨不忍睹"。但日本人没放弃，一直在孜孜不倦地研 究。我当时跟这个项目的主要科学家，其实算是医学家，是他组织起来，把这个东西真正推到了日本临 床上，他叫小野公二先生。 可能这也跟日本本身是唯一挨过原子弹、真被炸过的国家有关系。所以对它来讲，天然就对核，心里有 敬畏，或者 ...

范德堡大学团队研发的另一项技术聚焦心脏保存技术，通过夹闭主动脉向心脏注入含红细胞、保护液等 的冷却含氧液体，使心脏处于"放松休眠"状态后移植。首批3例成人受者在术后6个月心脏功能稳定无排 异反应，后续20例手术均获积极结果，且该技术同样适用于儿童群体。 纽约大学医学专家评价，这两项技术突破传统移植器官获取过程中的伦理与技术限制，为扩大移植供体 来源提供了关键性支撑，是器官移植领域的重要突破。 当前，心脏移植的供体主要依赖于脑死亡但心跳尚存的捐献者，但其数量远远难以满足临床需求。对于 心脏停跳5分钟后被宣告死亡的捐献者，现有复苏手段存在显著局限，如体外机器复苏设备成本高昂， 且无法适配体重不足40公斤的婴幼儿；体内复苏则因伦理争议难以推广，医生担忧其可能改变死亡原因 记录，或理论上存在恢复脑部血流的风险。 针对婴幼儿心脏移植技术难题，美国杜克大学团队研发的体外心脏复苏系统实现了技术突破。该系统通 过导管向主动脉泵入含氧血液，经左心室出口收集氧合后循环回输，使离体心脏恢复自主跳动。团队先 以仔猪验证可行性，之后，在今年完成了首例人体移植。他们把1个月大死亡婴儿的心脏，经体外重启 后，成功移植给3个月大的婴儿受者， ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 胸腔内淋巴结肿大 （ intrathoracic lymphadenopathy ） 是肺科医生经常面临的常见难题，表现为纵隔和肺门淋巴结的异常增大。胸腔内淋巴结肿大的最常见恶 性病因是 肺癌 ， 肺癌 是世界第一大癌症，也是癌症死亡的首要原因。据世界卫生组织国际癌症研究机构的数据，在 2022 年，全球估计新增肺癌病例约 250 万 例，死亡约 180 万例。此外，其他恶性肿瘤和良性疾病 （例如淋巴瘤、肺外肿瘤的胸腔内淋巴结转移、结节病、非特异性淋巴结炎、结核病等） 也可能表现为 胸腔内淋巴结肿大。对胸腔内淋巴结肿大的准确评估决定了疾病的诊断和分期，这对及时开展合理治疗至关重要。 2025 年 7 月 21 日，上海交通大学 孙加源 教授、 熊红凯 教授、 戴文睿 教授团队合作，在 Cell 子刊 Cell Reports Medicine 上发表了题为： Deep learning for detection and diagnosis of intrathoracic lymphadenopathy from endobronchial ultrasound mu ...

Core Insights - Thermo Fisher Scientific Inc. (TMO) is expected to report second-quarter 2025 results on July 23, with revenue estimates at $10.65 billion and earnings per share (EPS) at $5.22, indicating a slight revenue increase but a decline in earnings compared to the previous year [1][8] Revenue and Earnings Estimates - The Zacks Consensus Estimate for TMO's revenues is $10.65 billion, reflecting a 1% increase from the prior-year quarter [1] - The consensus estimate for earnings is $5.22 per share, indicating a 2.8% decline from the year-ago quarter [1][8] - Estimates for second-quarter earnings have remained unchanged at $5.22 per share over the past 60 days [2] Segment Performance - The Analytical Instruments segment is projected to generate $1.84 billion in revenues, suggesting a 3.3% year-over-year growth, driven by new AI-enabled platforms [6][8] - The Life-Science Solutions segment is expected to report $2.37 billion in revenues, indicating a 0.5% growth year over year, supported by proteomics and cell therapy initiatives [9][8] - The Specialty Diagnostics segment is anticipated to achieve $1.15 billion in revenues, reflecting a 2.9% growth year over year [11] - The Laboratory Products and Services segment is expected to see revenues of $5.71 billion, suggesting a decline of 0.7% year over year [13] Product Launches and Innovations - TMO launched several cutting-edge technologies, including the Krios 5 Cryo-TEM and the Invitrogen Attune Xenith Flow Cytometer, which are expected to contribute positively to second-quarter revenues [3][4] - The company also introduced the Vulcan Automated Lab and the Transcend ultra-high performance liquid chromatography platform, enhancing efficiency in various applications [5][4] Market Position and Outlook - TMO's strong performance in the Analytical Instruments and Life-Science Solutions segments is expected to bolster its overall revenue despite challenges in the Laboratory Products and Services segment [8][10] - The company has a Zacks Rank of 4, indicating a less favorable outlook for an earnings beat this reporting cycle, with an Earnings ESP of -0.35% [14]

Johnson & Johnson (JNJ) Q2 2025 Earnings Call July 16, 2025 08:30 AM ET Company Participants Darren Snellgrove - VP - IR Joaquin Duato - CEO, Chairman & Director Joseph Wolk - EVP & CFO Chris Schott - Managing Director Jennifer Taubert - EVP & Worldwide Chairman - Innovative Medicine Tim Schmid - EVP & Worldwide Chairman - MedTech John Reed - EVP - Innovative Medicine & R&D Alexandria Hammond - Director - Head of Therapeutics Conference Call Participants Terence Flynn - Equity Research Analyst Lawrence Bieg ...

Company Overview - Carlsmed Inc. plans to raise up to $107.2 million through an IPO, with a proposed share price range of $14 to $16 for 6.7 million shares, potentially valuing the company at approximately $424.3 million [1][2] - The company specializes in personalized surgical solutions and custom spinal implants using its AI technology platform, aprevo, which is currently approved for lumbar fusion surgeries [2] Financial Performance - For the first three months of 2025, Carlsmed reported revenues of $10.2 million and a net loss of $5.7 million, compared to revenues of $5.1 million and a net loss of $5.4 million in the same period the previous year [1] Market Context - The healthcare sector's IPO financing has been sluggish, with only $2.1 billion raised by new companies in this sector in 2025, representing a decline of over 40% compared to the same period in 2024 [1] - Carlsmed's major investors include B Capital Group and US Venture Partners, holding 35.1% and 28.3% of shares respectively prior to the IPO [2] Technology Development - The company is developing a version of its aprevo platform for cervical fusion surgeries, expected to be commercially available by 2026 [2] - As of March 2025, approximately 177 surgeons have utilized the aprevo platform for surgeries, an increase from 103 surgeons in the previous year [2] IPO Details - The IPO is being led by Bank of America, Goldman Sachs, and Piper Sandler Cos., with the stock expected to trade under the ticker symbol CARL on the Nasdaq Global Select Market [2]

Group 1 - The article discusses a training program for future leaders in the healthcare industry, focusing on strategic diagnosis and execution [2] - The program is scheduled to take place from July 11 to July 13 at two locations: Fujifilm Smart Medical Technology Training Center and Shanghai Jiao Tong University School of Medicine [2] - The agenda includes a workshop on corporate strategy and value engines led by Zhang Xiaopeng, who has extensive experience in healthcare management and leadership roles [5] Group 2 - On July 12, a workshop titled "Corporate Strategic Decision-Making and Growth Dilemmas Across Cycles" will be conducted by Zhang Landing, who has nearly 30 years of corporate management experience [6] - Zhang Landing is the chairman of Xiya Equity Investment Fund Management and has served as an independent director for several listed companies [6] - Participants interested in the course are encouraged to fill out a form to provide their basic information for further contact [6]

Group 1 - The EU is demanding immediate tariff reductions for key industries in any trade agreement reached with the US before the July 9 deadline, but expects some level of inequality in the agreement [1] - The EU has accepted a 10% baseline tariff as a non-negotiable bottom line while pushing for a principle agreement, with specific details to be finalized later [1] - Brussels is seeking to restore baseline tariffs to pre-Trump levels or achieve zero tariffs for specific industries, including alcoholic beverages and medical technology products currently subject to a 10% tariff [1] Group 2 - The EU's key demands include the elimination of a 25% tariff on automobiles and parts, and an immediate reduction of the recently increased 50% tariffs on steel and aluminum products [2] - The EU considers the automobile tariff a "red line," highlighting a fundamental conflict with the US, which aims to revitalize its automotive industry while the EU seeks to open its market due to high energy costs and competition from China [2] - The EU insists that any initial agreement should lead to immediate tariff reductions rather than waiting for a final agreement to be signed, with several member states stating that an agreement lacking this clause would be unacceptable [2] Group 3 - The EU Commission has informed its 27 member states that the negotiation outcomes could range from successfully signing a framework agreement to the US expanding its tariff range [3] - If immediate tariff reductions are not achieved, Brussels may face a dilemma of either accepting significantly imbalanced terms or initiating countermeasures [3] - Another possibility is extending the negotiation deadline, with the US Treasury Secretary indicating that any decision to delay rests with President Trump, but all agreements must be completed by September 1 [3]

Core Insights - The China International Import Expo (CIIE) serves as a significant platform for enhancing Swiss-Chinese economic and trade cooperation, acting as a "multiplier" for Swiss companies to expand in the Chinese market [1][3] - The Swiss Center has evolved into a key navigator for Swiss enterprises entering the Chinese market, helping over 100 companies participate in CIIE since its inception [2][3] Group 1: Swiss Center's Role - The Swiss Center has been a consistent participant in CIIE, helping Swiss companies, especially SMEs, showcase products and find business partners [2] - The Center has witnessed a growing recognition and satisfaction among Swiss enterprises regarding CIIE, with participation expanding from four companies in the first year to 24 companies in the seventh year [8][11] Group 2: Innovations and Developments - The Swiss Center has introduced a Business Development department to specifically support Swiss consumer goods companies, reflecting the increasing number of exhibitors at CIIE [6] - A new position, "Customer Success Manager," was created to assist Swiss companies in successfully entering the Chinese market, with a focus on reducing the product entry cycle from 12 months to 3 months [6][7] Group 3: Market Opportunities - CIIE provides Swiss brands with opportunities to test products, expand sales channels, and enter the Chinese market, leading to high participation enthusiasm among Swiss enterprises [11] - The introduction of an innovation incubation area at CIIE aims to meet the needs of Swiss startups looking to enter the Chinese market, showcasing 14 medical technology companies [11]